Eventide Asset Management LLC lowered its holdings in Korro Bio, Inc. (NASDAQ:KRRO - Free Report) by 26.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 391,166 shares of the company's stock after selling 137,989 shares during the quarter. Eventide Asset Management LLC owned about 4.21% of Korro Bio worth $13,073,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Brown Brothers Harriman & Co. bought a new position in shares of Korro Bio in the second quarter valued at $28,000. Quest Partners LLC raised its holdings in shares of Korro Bio by 172.1% in the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company's stock worth $59,000 after acquiring an additional 1,124 shares during the last quarter. MetLife Investment Management LLC lifted its position in Korro Bio by 129.0% in the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock valued at $122,000 after acquiring an additional 2,050 shares in the last quarter. Lynx1 Capital Management LP acquired a new position in Korro Bio during the 2nd quarter valued at about $129,000. Finally, BNP Paribas Financial Markets increased its holdings in Korro Bio by 1,018.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company's stock worth $164,000 after purchasing an additional 4,470 shares in the last quarter. Institutional investors own 13.18% of the company's stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on KRRO. HC Wainwright reaffirmed a "buy" rating and set a $115.00 target price on shares of Korro Bio in a research report on Friday, November 22nd. Royal Bank of Canada lifted their price objective on shares of Korro Bio from $95.00 to $105.00 and gave the stock an "outperform" rating in a report on Monday, October 21st. William Blair reiterated an "outperform" rating on shares of Korro Bio in a report on Wednesday, November 13th. Finally, Raymond James assumed coverage on shares of Korro Bio in a report on Monday, October 21st. They set a "strong-buy" rating and a $153.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Korro Bio has an average rating of "Buy" and a consensus target price of $142.17.
Check Out Our Latest Research Report on KRRO
Korro Bio Price Performance
Shares of NASDAQ:KRRO traded down $2.93 during midday trading on Friday, reaching $52.06. The company had a trading volume of 39,542 shares, compared to its average volume of 70,430. Korro Bio, Inc. has a 52-week low of $30.00 and a 52-week high of $98.00. The company's 50 day moving average price is $52.45 and its 200 day moving average price is $46.52.
Korro Bio (NASDAQ:KRRO - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating analysts' consensus estimates of ($2.55) by $0.29. On average, equities research analysts forecast that Korro Bio, Inc. will post -9.63 earnings per share for the current year.
Insider Buying and Selling at Korro Bio
In related news, CFO Vineet Agarwal sold 800 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.40% of the stock is owned by corporate insiders.
Korro Bio Profile
(
Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
See Also
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
